BioCentury | Sep 8, 2017
Clinical News

Tasly, FDA discuss approval path for Chinese medicine product

...Shanghai:600535) to conduct an additional Phase III trial before it submits an NDA for Dantonic (T89...
...new trial. Tasly and FDA met to discuss the potential of an accelerated approval of Dantonic...
...May 12 ). Tasly Pharmaceutical Co. Ltd. (Shanghai:600535), Tianjin, China Product: Dantonic (T89) Business: Cardiovascular Alicia Parker Dantonic T89 Tasly...
BioCentury | Aug 31, 2017
Company News

Tasly, FDA discuss approval path for Chinese medicine product

...Shanghai:600535) to conduct an additional Phase III trial before it submits an NDA for Dantonic (T89...
...new trial. Tasly and FDA met to discuss the potential of an accelerated approval of Dantonic...
...stable angina based on results of the 960-patient Phase III CAESA trial. Compared to placebo, Dantonic...
BioCentury | May 12, 2017
Company News

Pharnext, Tasly forming drug combo JV

...sorbitol, has Orphan Drug designation in the U.S. and EU. According to ClinicalTrials.gov, Tasly's Dantonic (T89...
BioCentury | May 10, 2017
Company News

Pharnext, Tasly to form drug combo JV

...sorbitol, has Orphan Drug designation in the U.S. and EU. According to ClinicalTrials.gov, Tasly's Dantonic (T89...
Items per page:
1 - 4 of 4